
|Videos|October 21, 2022
Enfortumab Vedotin (EV) Monotherapy and Pembrolizumab (P) Combination Treatments in Urothelial Cancer
Arlene Siefker-Radtke, MD, opens a discussion recapping the ESMO 2022 conference surrounding advanced and metastatic urothelial cancer.
Advertisement
Episodes in this series

Now Playing
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
In Its 50th Year, ESMO Comes to Berlin, a City Transformed
2
Medicare State Rankings Reveal Stark Differences in Access, Quality, and Affordability
3
Physical Activity, Vaccination May Protect Against Long COVID
4
AI Tools Reduce Burnout in Health Care Workers
5